Keywords: Protease-activated receptor 1; Doxorubicin; Heart failure; Vorapaxar;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Aspirin; Corticosteroids; Macrolides; Pneumococcus; Protease-activated receptor 1; Statins; Streptococcus pneumoniae; Vorapaxar;
Keywords: Vorapaxar; Heart surgery; Clinical outcomes; Mortality; Efficacy; Bleeding; Clinical trials;
Keywords: Myocardial infarction; Peripheral artery disease; Protease-activated receptor 1; Stent thrombosis; Stroke; Vorapaxar
Keywords: Vorapaxar; Ticagrelor; Trial conduct; Data censoring; Clinical trials
Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells
Keywords: Protease-Activated Receptor; PAR1; PAR2; GPCR; Calcium mobilization; Parmodulin; ML161; Vorapaxar; RWJ-58259; Negative allosteric modulator;
Protease-Activated Receptor-1 Antagonists Post-Percutaneous Coronary Intervention
Keywords: Antiplatelet therapy; Coronary artery disease; Protease-activated receptors; Vorapaxar; Myocardial infarction; Percutaneous coronary intervention;
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis
Keywords: aspirin; cangrelor; clopidogrel; prasugrel; ticagrelor; vorapaxar; ACS; acute coronary syndromes; CABG; coronary artery bypass graft; CAD; coronary artery disease; COX; cyclooxygenase; DAPT; dual antiplatelet therapy; ICH; intracranial hemorrhage; MI; myo
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial
Keywords: aspirin; Bleeding Academic Research Consortium; clopidogrel; mortality; vorapaxar; BARC; Bleeding Academic Research Consortium; CABG; coronary artery bypass graft; CI; confidence interval; eCRF; electronic case report form; GUSTO; Global Use of Strategies
Redesigning TRACER trial after TRITON
Keywords: Clinical trials; Trial design; Vorapaxar; Prasugrel; Outcomes;
Molecular and cellular pharmacologyPlatelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist
Keywords: Aspirin; Blood platelets; Clopidogrel; Hemorrhage; Vorapaxar;
Full Length ArticlePlatelet function recovery following exposure to triple anti-platelet inhibitors using an in vitro transfusion model
Keywords: Vorapaxar;; Clopidogrel;; Aspirin;; Platelet aggregation;; Platelet transfusion;
In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist
Keywords: PAR1; protease activated receptor 1; huCASMC; human coronary artery smooth muscle cells; HCl; hydrochloric acid; MgCl2; magnesium chloride; CaCl2; calcium chloride; NaCl; sodium choride; KCl; potassium chloride; K2HPO4; dipotassium phosphate; EGTA; ethyle
GuÃa ESC 2015 sobre el tratamiento de los sÃndromes coronarios agudos en pacientes sin elevación persistente del segmento ST
Keywords: Cuidados coronarios agudos; SÃndromes coronarios agudos; Angioplastia; Anticoagulación; Apixabán; Ácido acetilsalicÃlico; Aterotrombosis; Bloqueadores beta; Bivalirudina; CirugÃa de revascularización coronaria; Cangrelor; Unidad de dolor torácico;
Discovery of nor-seco himbacine analogs as thrombin receptor antagonists
Keywords: Vorapaxar; PAR-1; Thrombin receptor antagonist; SCH 530348; Platelet aggregation; Himbacine
Safety of the Novel Protease-Activated Receptor-1 Antagonist Vorapaxar in Japanese Patients with a History of Ischemic Stroke
Keywords: Atherothrombotic disease; ischemic stroke; protease-activated receptor antagonist; protease-activated receptor-1; PAR-1; vorapaxar
Determination of a novel thrombin receptor antagonist (SCH 530348) in human plasma: Evaluation of Ultra Performance Liquid Chromatography™–tandem mass spectrometry for routine bioanalytical analysis
Keywords: SCH 530348; Thrombin receptor antagonist; Vorapaxar; UPLC; UPLC–MS/MS; Bioanalytical method validation